Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 6/20 | 0.60 |
| ▸ | GRM3 | Q14832 | 6/20 | 0.60 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CCR8 | P51685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8764665 | 0.93 | GRM2 (0.63) | GRM2GRM3GRM8GRM4FFAR4 | |
| SCHEMBL8764011 | 0.89 | GRM2 (0.56) | GRM2GRM3GRM8GRM4FAAH | |
| SCHEMBL8763689 | 0.86 | GRM2 (0.59) | GRM2GRM3GRM8GRM4FFAR4 | |
| SCHEMBL8892624 | 0.86 | GRM2 (0.65) | GRM2GRM3GRM8GRM4 | |
| SCHEMBL8764744 | 0.86 | GRM2 (0.65) | GRM2GRM3GRM8GRM4 | |
| SCHEMBL8762578 | 0.84 | GRM2 (0.56) | GRM2GRM3GRM8GRM4EPHX2 | |
| SCHEMBL8762579 | 0.83 | GRM2 (0.63) | GRM2GRM3GRM8GRM4FAAH | |
| SCHEMBL8763907 | 0.83 | GRM2 (0.69) | GRM2GRM3GRM8GRM4 | |
| SCHEMBL8764458 | 0.79 | GRM2 (0.64) | GRM2GRM3GRM8GRM4 | |
| SCHEMBL8764439 | 0.77 | GRM2 (0.81) | GRM2GRM3GRM8GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0774455-A1 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |